<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645632</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582263</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>909101</secondary_id>
    <secondary_id>549-90</secondary_id>
    <nct_id>NCT00645632</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma</brief_title>
  <official_title>Treatment of Newly Diagnosed Untreated Osteosarcoma: A Pilot Study of a New Chemotherapeutic Regimen Including Ifosfamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as ifosfamide, methotrexate, cisplatin, and&#xD;
      doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving chemotherapy before surgery may make the&#xD;
      tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it&#xD;
      after surgery may kill any tumor cells that remain after surgery.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating&#xD;
      patients undergoing surgery for newly diagnosed high-grade osteosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the efficacy of a new induction regimen comprising ifosfamide in combination&#xD;
           with high-dose methotrexate, cisplatin, and doxorubicin hydrochloride, in terms of&#xD;
           clinical response and pathological response of the tumor, in patients with newly&#xD;
           diagnosed high-grade osteosarcoma.&#xD;
&#xD;
        -  To determine the overall survival and disease-free survival of these patients.&#xD;
&#xD;
        -  To evaluate the toxicity of this regimen.&#xD;
&#xD;
        -  To correlate MRI imaging of the primary tumor with histopathologic grading after&#xD;
           treatment with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Neoadjuvant chemotherapy (weeks 1-15): Patients receive ifosfamide IV over 1 hour on&#xD;
           days 1-5 and 36-40; doxorubicin hydrochloride IV over 18 hours on days 1-3 and 36-38 and&#xD;
           IV over 72 hours on days 71-73; high-dose methotrexate IV over 4 hours on days 22, 29,&#xD;
           57, 64, 92, and 99; and cisplatin IV over 4 hours on day 71.&#xD;
&#xD;
        -  Surgery (week 16): Patients undergo resection of the tumor on day 106. Patients found to&#xD;
           have unresectable disease are treated on an alternative protocol unless they have clear&#xD;
           clinical and pathologic response to treatment.&#xD;
&#xD;
        -  Adjuvant chemotherapy (weeks 18-43): Beginning 2 weeks after surgery, patients receive&#xD;
           ifosfamide IV over 1 hour on days 120-124, 155-159, 225-229, and 260-264; doxorubicin&#xD;
           hydrochloride IV over 18 hours on days 120-122 and 155-157 and IV over 72 hours on days&#xD;
           190-192; high-dose methotrexate IV over 4 hours on days 141, 148, 176, 183, 211, 218,&#xD;
           246, 253, 281, and 288; and cisplatin IV over 4 hours on days 190 and 289.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 2 months for 1 year, every 4&#xD;
      months for 2 years, every 6 months for 2 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1990</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 1995</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathologic response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed osteosarcoma of the extremity&#xD;
&#xD;
               -  High-grade (grade III or IV) disease&#xD;
&#xD;
                    -  No low-grade disease (e.g., parosteal or periosteal osteosarcoma)&#xD;
&#xD;
          -  No secondary osteosarcoma (i.e., tumor occurring in a radiotherapy field designed for&#xD;
             a prior tumor)&#xD;
&#xD;
          -  No Paget's disease&#xD;
&#xD;
          -  No known metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Total bilirubin &lt; 2 times normal&#xD;
&#xD;
          -  AST &lt; 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  LVEF ≥ 45%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other prior malignancy except retinoblastoma&#xD;
&#xD;
               -  Patients with familial retinoblastoma syndrome who develop osteosarcoma unrelated&#xD;
                  to radiotherapy (e.g., in a primary site in the extremities) are eligible&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy&#xD;
&#xD;
               -  Patients with retinoblastoma may have received radiotherapy to the orbits&#xD;
&#xD;
          -  At least 28 days since prior initial amputation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald S. Gilchrist, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom R Fitch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerardo Colon-Otero, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carola A.S. Arndt</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>localized osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

